Regeneron Pharmaceuticals Inc (NASDAQ:REGN) decreased 2.39%
to $133.57. According to report from Reuters,
U.S. Food and Drug Administration has approved Sanofi SA's and Regeneron
Pharmaceuticals Inc's Zaltrap for use in combination with a folinic acid,
fluorouracil and irinotecan chemotherapy regimen to treat adults with
colorectal cancer.
The Street Ratings upgraded the rating on the stock from
hold to buy.
Get daily Updates On Healthcare
Sector Here
Galena Biopharma Inc (NASDAQ:GALE) surged up 4.70% to $1.56.
The Company announced the issuance of a patent from the Japan Patent Office for
a Composition of Matter and Method of Treatment patent covering Folate Binding
Protein peptide variants for use either alone or in combination with the FBP
cancer vaccine, E39. The Japanese patent provides exclusivity in the country
until 2022 with additional worldwide patent filings pending.
Taro Pharmaceutical Industries Ltd (NYSE:TARO) declined
3.59% to $39.50. Sun Pharmaceutical Industries Ltd and Taro Pharmaceutical
Industries Ltd have entered into a merger agreement together with certain
affiliates of Sun Pharma. The
shareholders of Taro will receive a cash payment of $39.50 per share upon the
closing of the merger. Taro will become a privately held company and will be
wholly owned by affiliates of Sun Pharma after the completion of the merger.
Can TARO Bounce Back After Today’s
Fall? Find Out Here
Sanofi SA (ADR) (NYSE:SNY) went down 0.48% to $41.40. The
Company said that U.S. Food and Drug Administration have approved Auvi-Q for
the emergency treatment of life-threatening allergic reactions in people who
are at risk for or have a history of anaphylaxis.
Elan Corporation plc (ADR)
(NYSE:ELN) increased 5.32% to $11.68. The Company would spin off its Neotope
drug discovery business platform as a separate public company. The decision to
split the company was due to the failure of an experimental Alzheimer's drug
being developed with Pfizer and Johnson & Johnson. The completion of the
spin-off is expected by the end of 2012.
No comments:
Post a Comment